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Abstract
Background: Breast cancer (BC) is the most frequent cancer occurring in women across the world. Its mortality rate
in low-middle income countries (LMICs) is higher than in high-income countries (HICs), and in Indonesia BC is the
leading cause of cancer deaths among women. Delay in breast cancer diagnosis negatively impacts cancer
prognosis. Only about 30% of patients who come to the hospital to check on their breast abnormalities, continue
thorough examination to biopsy to get a diagnosis based on the results of anatomical pathology. Many Indonesian
women with breast cancer were already in an advanced stage when starting treatment. Therefore, delay in
diagnosis is a serious problem that needs to be addressed. The present study will investigate whether our newly
developed self-help psycho-educational programme, “PERANTARA”, for women with breast cancer symptoms is
effective to reduce patient diagnosis delay in Indonesia.
Methods: A cluster-randomized controlled trial will be conducted in 106 patients in four hospitals in Bandung,
West Java, Indonesia. Data will be collected at baseline (pre-assessment), 7 days after the intervention (post-
assessment), and at 3 months (follow-up assessments). The primary outcome is delay in diagnosis and treatment.
Secondary outcomes are breast cancer knowledge, anxiety and depression, and quality of life. Exploratively,
adherence with treatment will be measured too. Data will be analysed by hierarchical linear modelling (HLM) to
assess differential change over time.
Discussion: If proven effective, PERANTARA will be evaluated and implemented in a diversity of settings for local
cares (such as in POSYANDU, PUSKESMAS) that provide health education/psycho-education for women with breast
symptoms.
Trial registration: ISRCTN12570738. Date: November 19th, 2016.
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Background
Breast cancer (BC) is the most frequent cancer occurring
and the leading cause of cancer-related deaths in
women, with an estimated 1.67 million new cancer cases
diagnosed and 522,000 deaths in 2012 [1]. The incidence
of breast cancer in LMICs is lower as compared to HICs
(25.8 vs 95 per 100.000), but a major concern in LMICs
is the higher mortality despite its lower incidence (12.7
vs 17.1 per 100.000) [2]. In Indonesia, BC is the most
prevalent cancer among women with an incidence rate
of 48,9 and a mortality rate of 19,8 women per 100,000
[3].
One of the reasons for the high mortality of breast
cancer in LMICs is the fact that most cancer in LMICs
is detected at later stages. Review on delay of diagnosis
revealed that more than 70% of breast cancer patients in
most HICs are diagnosed in Stages I and II, compared
with only 20 to 50% of patients in the majority of LMICs
[4]. In Indonesia, about 60%–70% of patients had their
first BC-related visit to the hospital when the disease
was already in advanced stages (III and IV) [5–7].
Diagnosis delay, the time between seeking medical ad-
vice and the date of final diagnosis based on pathological
examination (i.e. biopsy), remains a serious problem.
Studies have shown that diagnosis delay of over 3
months is associated with a bigger tumour size, positive
lymph nodes, high incidence of late clinical stages, and
metastatic disease [8, 9]. Delay in diagnosis predicts
worse clinical outcomes [10]. The delay may cause mor-
tality of the patient. A previous qualitative study involv-
ing 50 BC patients in Indonesia found that 35
participants (70%) were delayed in seeking help, with the
time of delay ranging from 4 to 24 months, except for
the four participants who had delayed for 4 years,
10 years, 3 years, and 15 years, respectively [11].
Previous studies found that delay in diagnosis among
women with breast cancer symptoms was a result of a
complex interaction of several factors, which often con-
cern characteristics of the patients and the health care
system. Several studies state that patients-related factors
are a major concern and need to be addressed in an
intervention program (e.g. lack of knowledge and aware-
ness about breast cancer). For example, a study in Mo-
roccan women found that diagnosis delay is also a very
important health problem in Moroccan women, particu-
lary caused by a lack of knowledge, information and
awareness regarding breast cancer [12].
As diagnostic delay is a serious problem, efforts to re-
duce delay are necessary. Improving knowledge of
women, via training and involving physicians and other
healthcare providers, seems to be an effective approach
to reduce delay in the diagnosis of breast cancer [13].
The delay to consult a doctor for seeking help after the
discovery of the symptoms is most likely caused by lack
of awareness and inadequate knowledge about symp-
toms and treatment of BC [11, 14, 15]. It is crucial that
the information that is provided by the medical staff, is
both informative and acceptable to patients.
A cross-sectional study in 70 breast cancer patients in
Indonesia showed also that many breast cancer patients
in Indonesia were not satisfied with the information they
received [16]. The study showed that most patients were
dissatisfied with the information about social support.
Furthermore, the study found also that most of the pa-
tients were dissatisfied with the amount of written infor-
mation. Therefore, the use of clear, concise, and easy to
understand educational materials (e.g.: leaflets, posters,
flipcharts table, visualized story telling) may be effective
and efficient in complementing the verbal information
that is usually provided by the oncologists at the oncol-
ogy clinic. The utilization of educational material may
be a solution to overcome the lack of resources (e.g. : ex-
perts, time and finance) and can be given by a face-to-
face breast health education, either individually or in
groups.
Numerous psycho-educational interventions have been
designed for women (affected by) with breast cancer (or
breast cancer symptoms) in response to the need for
psychological support and health behavior education. A
randomized controlled trial (an experimental pretest-
posttest control group design) involving 76 women with
BC in Turkey comparing a psycho-education program to
treatment as usual reported that the psycho-educational
program (which consisted of eight 90 min weekly ses-
sions on basic information about breast cancer, nutri-
tion, psychosocial factors, interpersonal skills, problem
solving, experience sharing and support) led to positive
changes in levels of adjustment to cancer [17]. In that
study, the psycho-educational group had higher levels of
fighting spirit, lower levels of helplessness/hopelessness,
anxious preoccupation and fatalism, both at 6 weeks and
6 months after the intervention. However, there were no
changes in the levels of avoidance/denial compared to
the control group. Another study (one group pre-post
test design) carried out in early-stage BC patients in Italy
found that a psycho-educational intervention was feas-
ible and useful to enhance coping strategies in patients
[18]. An RCT that evaluated the efficacy of a psycho-
educational intervention (an individualized fatigue edu-
cation and support program delivered in the clinic and
by phone over three 10- to 20-min sessions 1 week
apart) in improving BC-related fatigue compared to gen-
eral cancer educational sessions (equivalent in number
and timing to the sessions that were provided for the
intervention group) suggests that women who received
the intervention received some short-term benefit in
terms of minimization of the intensity and impact of fa-
tigue on daily life [19]. A systematic review and meta-
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analysis to evaluate the effectiveness of psychosocial and
especially psycho-educational support interventions for
early-stage breast cancer patients showed that these in-
terventions were effective in increasing emotional well-
being [20]. An intervention study that aimed to assess
the effectiveness of psycho-education on well-being sta-
tus and depression among Malaysian BC patients using
cluster non-randomized trial design found that group
psycho-education not only significantly improved breast
cancer survivors’ well-being status but also reduced de-
pression level [21].
Web-based programs are a promising new way to offer
psycho-educational interventions to patients and their
caregivers [22], but several patient groups in Indonesia
have no access to it, particularly patients with low edu-
cation, low socio-economic status (SES) and those in
rural areas. Currently in Indonesia, printed and on-line
information materials about BC have been provided by
hospitals, the Ministry of Health and a number of foun-
dations or communities. However, these sources of in-
formation appeared to not have achieved an optimal
impact either, due to the lack of capacity to access them,
particularly for patients with low socio-economic status
(SES) in rural areas. Meanwhile, the information that is
accessible to the wider public (TV, radio, and newspa-
pers) often contains promotion of traditional healing
methods which even can make patients hesitant in fol-
lowing the process of examination (and possible treat-
ment) at the regular hospital.
Summarizing, several educational interventions for
breast cancer patients exist, but these focus mainly on
coping with cancer. Interventions which focus on the re-
duction in diagnosis delay, are less common, and absent
in Indonesia. Therefore, an educational program to dimin-
ish diagnosis delay can be of paramount importance for
reducing morbidity and death. For this purpose, we devel-
oped a psycho-educational intervention (‘PERANTARA’)
focused on reducing diagnosis delay.
The aim of this study is to evaluate the effectiveness of
PERANTARA in reducing the delay of breast cancer diag-
nosis in women who visit the hospital with BC symptoms
prior to formal BC diagnosis based on pathological exam-
ination. As a secondary aim, we studied its effect on breast
cancer knowledge, anxiety and depression, and quality of
life. Finally, we explored the effects on the longer term,
also regarding the treatment delay.
Methods
Design
The study will be a multicentre, cluster-randomized con-
trolled trial (cRCT), with hospitals as the unit of ran-
domisation (clusters). We will include four hospitals in
Bandung, Indonesia that have agreed to participate in
this study. Because of the limited number of hospitals,
we will use a cross-over design in which in each hospital
will be given PERANTARA or control (treatment as
usual (TAU)) at successive periods. Because every hos-
pital forms its own control, the cross-over design can
produce results with a smaller sample size than required
with a parallel design. The order in which the hospital
receives PERANTARA is randomly determined. The
study will compare the PERANTARA to TAU in women
with suspected breast cancer. This study uses two prede-
fined periods. In the first period, two hospitals will have
the experimental group (the patient is given the inter-
vention and TAU) and two other hospitals will have the
control group (patients only receive TAU). In the second
period, it is the other way around.
The primary outcome is diagnosis delay in terms of
the time between the date of the first consultation at the
hospital and the date of final breast cancer diagnosis
based on pathological examination. Secondary outcomes
are breast cancer knowledge, anxiety and depression,
and quality of life, as well as treatment delay.
Participants
This study will include 106 patients in the cRCT, 53 par-
ticipants in the Treatment-as-Usual (TAU) control group
and 53 participants in the experiment/intervention
group. Power calculations suggest a minimum sample
size of 41 participants per group (power = 0.80, alpha =
.05 two-sided). Taking into account 30% attrition at
follow-up, at least 106 participants (53 per group) need
to be included. Participants will be recruited from four
district hospitals in Bandung, West Java, Indonesia, that
are representative for the health care facilities in the dif-
ferent areas in Bandung, Indonesia.
Participants will be new patients (outpatients) who
visit the hospital with breast symptoms, which make
them suspects of having breast cancer. Patients eligible
for the intervention program will be asked to take part
in the study when reporting at the district hospitals. The
following inclusion criteria will be used: women with
age > 18 years, an adequate command of the Indonesian
language and no major psychiatric disorder. The last is
determined by checking the medical record on a con-
sultation history/record with the Psychiatric Depart-
ment. Patients who have been seen by psychiatrists are
excluded from the study.
Procedure
The healthcare professionals (oncologist or nurse) will
inform eligible participants about the study (see Fig. 1).
The research assistant will follow up to inform the pa-
tients about the details of the study and asks them for
oral and written informed consent. Patients who agree
to participate will be asked to fill in: (1) the socio-
demographic and medical history form, (2) the World
Setyowibowo et al. BMC Cancer  (2017) 17:284 Page 3 of 8
Health Organization Quality of Life - Assessment Bref
(WHOQOL-BREF), (3) the European Quality of Life-5
Dimensions-5 Levels (EQ-5D-5 L), (4) the Hospital
Anxiety-Depression Scale (HADS) Questionnaire, (5) the
Breast Cancer Knowledge Test (BCKT). Participants
who are illiterate will be giving an oral consent and a
thumb print in lieu of a signature, in line with recom-
mendations from WHO [23].
Participants in the control group will receive treatment
as usual (TAU), while the intervention group will receive
the PERANTARA package (which consists of printed
and audiovisual materials). Participants will be requested
to read and watch the intervention package within
7 days.
The post-intervention assessment will take place 7 days
after the intervention. Participants will be asked to fill in
the following questionnaires: (1) the Diagnostic Delay
Questionnaire; Quality of Life (2) WHOQOL-Bref and
(3) EQ-5D 5L; (4) HADS; (5) BCKT; (6) Intervention
Material Feedback Form.
The follow up assessment will be scheduled at
3 months (12 weeks) after the post-intervention assess-
ment. The Participant will be requested to fill in: (1) The
Diagnostic Delay Questionnaire; Quality of Life (2)
WHOQOL-Bref and (3) EQ-5D 5L; (4) HADS; (5)
BCKT. The researcher will review the medical record of
the patient to registrate the occurence of treatment
delay. This period is chosen because it is also a criterion
for treatment delay.
Trained research assistants with a background of
psychology will conduct the assessments. All research
assistants have received a 5-days workshop covering
how to administer the instruments, information on com-
mon psychosocial needs of breast cancer patients, gen-
eral interview techniques, and how to take a neutral role
instead of a therapeutic role. Ongoing monitoring will
be conducted through regular supervision by the main
researcher (HS) supervised by the principle investigators.
Intervention
The ‘PERANTARA’ is a self-help psycho-education
material package that consists of both printed and au-
diovisual material (see Table 1). The word PERAN-
TARA is Indonesian for ‘mediator’ or ‘facilitator’.
PERANTARA is abbreviation for “Pengantar PERAwa-
taN kesehaTan payudARA”, which means ‘introduc-
tion to breast health treatment’. The conceptual
framework (blueprint) of PERANTARA was developed
based on semi-structured interviews with 27 breast
cancer patients and 5 focused group discussion ses-
sions with healthcare providers (5 oncologists and 15
nurses). The conceptual framework (blueprint) was
then reviewed by a panel consisting of a health
psychology expert, a healthcare communication ex-
pert, an oncologist, and a breast cancer survivor. The
researchers obtained suggestions and comments on
the intervention blueprint and also the usability and
acceptability of the developed interventions. The
panel also recommended to have the printed and au-
diovisual material be developed by a team of audiovi-
sual professionals. The PERANTARA provides the
following information: 1) a brief explanation of breast
cancer in order for the patients to have an accurate
understanding and stimulation to seek information
from reliable sources (oncologist); 2) an explanation
of the breast examination procedure to raise the pa-
tients’ awareness on their symptoms and willingness
to follow this procedure; 3) recommendation to seek
support from significant persons and institutions. The
audiovisual material is an 8 min and 33 s length
video featuring two breast cancer survivors who
shared their stories about their conditions, promoting
active coping and seeking social support.
The prototype of PERANTARA was piloted within 13
patients and with oncologists and survivors. Results
from this pilot study showed that the prototype was
Fig. 1 Flowchart of The Procedure
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feasible and acceptable to use. Trained research assis-
tants will give the PERANTARA to the experimental
groups. They will give a brief explanation to the patient
regarding PERANTARA and instructions on how to
use it.
Treatment as usual (TAU)
TAU in a district hospital usually consists of consult-
ation with the oncologist about the medical examination
procedures. Information related to breast health is lim-
ited, and usually entails nothing more than a poster on
the wall in the hospital waiting room. Psychosocial ser-
vices for patients with breast complaints to support the
patient during the examination process are not provided
at all four hospitals participated in the study. The re-
search assistants will keep track of all services received
by the patients during the course of the study.
Instruments
Primary outcome
Diagnosis delay will be the primary outcome measure.
This is defined as the time between the date of the first
consultation at the hospital and the date of the definite
breast cancer diagnosis based on pathological examin-
ation. This outcome will be measured using the Diag-
nostic Delay Interviewer Guide. This instrument has
been developed by the researchers and consists of the
following questions: (a) What was the date that you
Table 1 Overview of PERANTARA Package
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consulted with a doctor in the hospital?, (b) What was
the date that you received the breast cancer diagnosis?,
and if there was a consult delay (c) What were the rea-
sons for delay? A distinction will be made between delay
due to the patient and due to the doctor. This tool will
be pilot-tested before the final data collection is done.
Secondary outcome
A standard socio-demographic and medical history form
(SDMH) will be used to collect patients’ background
data on ethnicity, age, marital status, religion, education
level, employment status, income level, travel time to
hospital, insurance status, mental health status, family
history of cancer and use of traditional healer. The pa-
tients’ medical records will also be reviewed to obtain
data on type and stage of cancer and type of treatment.
Patient knowledge will be assessed using the Breast
Cancer Knowledge Test (BCKT). The BCKT is a 20-item
questionnaire that was developed and tested to deter-
mine (a) general knowledge of breast cancer; and (b) the
relationship between the knowledge of breast cancer and
utilization of screening practices. The BCKT consists of
2 subscales; one subscale of 12 items to measure general
knowledge and one subscale consisting of 8 items to
measure knowledge of curability. In the first section,
item number 3 about the breast cancer prevalence was
adjusted with the actual Indonesian prevalence rate. The
total score ranged from 0 to 20, with higher scores indi-
cating higher breast cancer knowledge. The BCKT has
an acceptable reliability coefficient (α = 0.69). The Breast
Cancer Knowledge Test (BCKT) has been translated into
Indonesian using the forward-backward translation
method [24].
Symptoms of anxiety and depression will be measured
with the Hospital Anxiety and Depression Scale (HADS).
The HADS is a 14-item self-report questionnaire that
was developed to assess psychological distress in people
with medical illness. It consists of 2 subscales: 7 items to
measure anxiety (HADS-A) and 7 items to measure de-
pressive symptoms (HADS-D). Psychometric properties
of the Indonesian version of the HADS were adequate,
with values of Cronbach’s coefficient (alpha) being 0.77
and 0.74, respectively [13].
Quality of life will be measured using the WHOQOL-
BREF ([25]; in the Indonesian version with a 4 week-
time frame). This tool is a self-report questionnaire that
consists of 26 items and each item represents one facet
of life that is considered to have a contribution to a per-
son’s quality of life. Two items measure quality of life
and health satisfaction in general. Twenty-four items
measure four broad domains, namely physical health (7
items), psychological health (6 items), social relation-
ships (3 items) and environmental (8 items). The
WHOQOL-BREF has been validated, and indicates high
validity and reliability for measuring the quality of life
among the elderly [26]. We will also use the EQ-5D 5L
to measure health-related quality of life [27]. EQ-5D 5L
is based on a descriptive system that defines health in
terms of 5 dimensions: mobility (MO), self-care (SC),
usual activities (UA), pain/discomfort (PD), and anxiety/
depression (AD). Each dimension has 5 levels: no prob-
lems, slight problems, moderate problems, severe prob-
lems, and extreme problems/unable. This descriptive
system is then followed by a self-rating of overall health
status on a visual analogue scale (EQ - VAS) ranging
from 0 (“the worst health you can imagine") to 100 (“the
best health you can imagine"). EQ-5D 5L has been
validated in diverse patient populations in numerous
countries [28]. The official Bahasa Indonesia version
of the EQ-5D 5L will be used; provided by the Euro-
Qol Group [29].
Feedback from participants on the intervention mater-
ial package will be measured using The Intervention
Material Feedback Form. This instrument has been de-
veloped by the researchers. Finally, treatment delay will
be measured at the follow-up measurement by asking
the patient with a positive diagnosis if she has started
her treatment at the hospital. This will also be checked
with the hospital records.
Analysis plan
Demographic characteristics will be summarized using
descriptive statistics, including percentages for categor-
ical data, and means and standard deviations for con-
tinuous data. The descriptive statistics will be tabulated
and presented graphically. Hierarchical linear modeling
(HLM) will be employed to evaluate potential changes in
the Diagnostic Delay Questionnaire scores over time. In
this study, a three level model will be used with repeated
measures nested in person, and persons nested in clus-
ters. Time (pre, post, follow-up) will be considered as
level 1, the individual persons will be considered as level
2 and the clusters (intervention-control group) will be
considered as level 3. HLM analysis using a similar
model will also be carried out to evaluate potential
changes in the scores of secondary outcomes: Quality of
Life (WHOQOL-BREF and EQ-5D 5L), HADS, and
BCKT respectively. HLM analysis will be carried out
separately for each phase before and after crossover.
Demographic variables will be entered as additional
predictors including SES, educational levels, and
patients’ locations to explore potential impact on the
effect of the interventions.
Ethics
The project has been approved locally by the Health Re-
search Ethics Committee of Dr. Hasan Sadikin General
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Hospital Bandung on December 23rd, 2013, Document
No: LB.04.01/A05/EC/127/XII/2013 (Additional file 1).
Discussion
Delivering self-help psycho-education materials, expli-
citly aimed at diagnosis delay – like our PERANTARA -
may be an effective way to offer psycho-educational in-
terventions. Therefore, this study has been designed to
evaluate the effectiveness of self-help psycho-education
materials in reducing the delay of breast cancer diagno-
sis in women who visit the hospital with BC symptoms
prior to formal BC diagnosis based on pathological
examination. If proven effective, PERANTARA will be
evaluated and implemented in a diversity of settings of
primary care (such as in PUSKESMAS, POSYANDU),
which provide health education/psycho-education for
women with breast symptoms who are liable to BC diag-
nosis delay.
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Additional file 1: Ethical clearance approval. (PDF 626 kb)
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